Premium
Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases
Author(s) -
Dichiara Maria,
Marrazzo Agostino,
Prezzavento Orazio,
Collina Simona,
Rescifina Antonio,
Amata Emanuele
Publication year - 2017
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201700259
Subject(s) - biology , repurposing , neglected tropical diseases , african trypanosomiasis , kinase , leishmaniasis , drug repositioning , leishmania , trypanosoma , protozoan parasite , trypanosomiasis , computational biology , disease , virology , immunology , genetics , pharmacology , medicine , drug , parasite hosting , ecology , pathology , world wide web , computer science
Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis belong to a group of infectious diseases known as neglected tropical diseases and are induced by infection with protozoan parasites named trypanosomatids. Drugs in current use have several limitations, and therefore new candidate drugs are required. The majority of current therapeutic trypanosomatid targets are enzymes or cell‐surface receptors. Among these, eukaryotic protein kinases are a major group of protein targets whose modulation may be beneficial for the treatment of neglected tropical protozoan diseases. This review summarizes the finding of new hit compounds for neglected tropical protozoan diseases, by repurposing known human kinase inhibitors on trypanosomatids. Kinase inhibitors are grouped by human kinase family and discussed according to the screening (target‐based or phenotypic) reported for these compounds on trypanosomatids. This collection aims to provide insight into repurposed human kinase inhibitors and their importance in the development of new chemical entities with potential beneficial effects on the diseases caused by trypanosomatids.